Vaccines against human diarrheal pathogens Current status and perspectives

DC FieldValueLanguage
dc.contributor.authorBoehles, Nathalie
dc.contributor.authorBusch, Kim
dc.contributor.authorHensel, Michael
dc.date.accessioned2021-12-23T15:57:40Z-
dc.date.available2021-12-23T15:57:40Z-
dc.date.issued2014
dc.identifier.issn21645515
dc.identifier.urihttps://osnascholar.ub.uni-osnabrueck.de/handle/unios/3054-
dc.description.abstractWorldwide, nearly 1.7 billion people per year contract diarrheal infectious diseases (DID) and almost 760 000 of infections are fatal. DID are a major problem in developing countries where poor sanitation prevails and food and water may become contaminated by fecal shedding. Diarrhea is caused by pathogens such as bacteria, protozoans and viruses. Important diarrheal pathogens are Vibrio cholerae, Shigella spp. and rotavirus, which can be prevented with vaccines for several years. The focus of this review is on currently available vaccines against these three pathogens, and on development of new vaccines. Currently, various types of vaccines based on traditional (killed, live attenuated, toxoid or conjugate vaccines) and reverse vaccinology (DNA/mRNA, vector, recombinant subunit, plant vaccines) are in development or already available. Development of new vaccines demands high levels of knowledge, experience, budget, and time, yet promising new vaccines often fail in preclinical and clinical studies. Efficacy of vaccination also depends on the route of delivery, and mucosal immunization in particular is of special interest for preventing DID. Furthermore, adjuvants, delivery systems and other vaccine components are essential for an adequate immune response. These aspects will be discussed in relation to the improvement of existing and development of new vaccines against DID.
dc.language.isoen
dc.publisherTAYLOR & FRANCIS INC
dc.relation.ispartofHUMAN VACCINES & IMMUNOTHERAPEUTICS
dc.subjectANTIGENIC VARIATION
dc.subjectBiotechnology & Applied Microbiology
dc.subjectCampylobacter spp.
dc.subjectdiarrheal diseases
dc.subjectEFFICACY TRIAL
dc.subjectENTEROTOXIGENIC ESCHERICHIA-COLI
dc.subjecthuman pathogen
dc.subjectIMMUNE-RESPONSES
dc.subjectImmunology
dc.subjectMASS VACCINATION
dc.subjectO-SPECIFIC POLYSACCHARIDE
dc.subjectORAL VACCINE
dc.subjectrecombinant vaccine
dc.subjectrotavirus
dc.subjectROTAVIRUS VACCINATION
dc.subjectShigella spp.
dc.subjectSHIGELLA-FLEXNERI 2A
dc.subjectVibrio cholerae
dc.subjectVIBRIO-CHOLERAE O139
dc.titleVaccines against human diarrheal pathogens Current status and perspectives
dc.typereview
dc.identifier.doi10.4161/hv.29241
dc.identifier.isiISI:000342763200020
dc.description.volume10
dc.description.issue6
dc.description.startpage1522
dc.description.endpage1535
dc.identifier.eissn2164554X
dc.publisher.place530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
dcterms.isPartOf.abbreviationHuman Vaccines Immunother.
dcterms.oaStatusGreen Published, Bronze
crisitem.author.deptFB 05 - Biologie/Chemie-
crisitem.author.deptidfb05-
crisitem.author.orcid0000-0001-6604-6253-
crisitem.author.parentorgUniversität Osnabrück-
crisitem.author.netidHeMi480-
Show simple item record

Page view(s)

2
Last Week
0
Last month
0
checked on May 19, 2024

Google ScholarTM

Check

Altmetric